{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:05:26Z","timestamp":1789826726855,"version":"4.0.1"},"reference-count":232,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003443","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-03-2026-024"],"award-info":[{"award-number":["075-03-2026-024"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials Advances"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioadv.2026.214829","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:03:14Z","timestamp":1774040594000},"page":"214829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nanoparticles for immobilization and delivery of temozolomide: Functional design of carriers, advances, limitations and opportunities for glioblastoma co-therapy"],"prefix":"10.1016","volume":"184","author":[{"given":"Gali","family":"Markova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilina","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Baranov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa","family":"Dvorikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Shulgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Shtilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslav","family":"Mezhuev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.bioadv.2026.214829_bb0005","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cncr.32328","article-title":"Glioma incidence and survival variations by county-level socioeconomic measures","volume":"125","author":"Cote","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-022-01298-0","article-title":"Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence","volume":"15","author":"Kreatsoulas","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-020-03451-6","article-title":"Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis","volume":"147","author":"Marenco-Hillembrand","year":"2020","journal-title":"J. Neurooncol"},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7030069","article-title":"Temozolomide and other alkylating agents in glioblastoma therapy","volume":"7","author":"Strobel","year":"2019","journal-title":"Biomedicines"},{"issue":"Supplement_5","key":"10.1016\/j.bioadv.2026.214829_bb0025","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2012\u20132016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bioadv.2026.214829_bb0030","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semcancer.2019.10.010","article-title":"Brain malignancies: glioblastoma and brain metastases","volume":"60","author":"Lah","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0035","article-title":"Extracranial glioblastoma metastasis: a neuropathological case report","volume":"15","author":"Stoyanov","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/20450907.2024.2351789","article-title":"Metastatic glioblastoma to the lungs: a case report and literature review","volume":"13","author":"Yuen","year":"2024","journal-title":"CNS Oncol."},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13020181","article-title":"Spinal metastasis in a patient with supratentorial glioblastoma with primitive neuronal component: a case report with clinical and molecular evaluation","volume":"13","author":"Hendrych","year":"2023","journal-title":"Diagnostics"},{"issue":"27","key":"10.1016\/j.bioadv.2026.214829_bb0050","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","article-title":"Glioblastoma heterogeneity at single cell resolution","volume":"42","author":"Eisenbarth","year":"2023","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002640","article-title":"Understanding glioblastoma at the single-cell level: recent advances and future challenges","volume":"22","author":"Yabo","year":"2024","journal-title":"PLoS Biol."},{"issue":"6","key":"10.1016\/j.bioadv.2026.214829_bb0060","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1111\/cas.15773","article-title":"Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma","volume":"114","author":"Wu","year":"2023","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.stemcr.2014.11.003","article-title":"Genetic and functional diversity of propagating cells in glioblastoma","volume":"4","author":"Piccirillo","year":"2015","journal-title":"Stem Cell Rep."},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0070","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3390\/ijms22126385","article-title":"Molecular mechanisms of drug resistance in glioblastoma","volume":"22","author":"Dymova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioadv.2026.214829_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.620677","article-title":"Drug resistance in glioblastoma: the two faces of oxidative stress","volume":"7","author":"Olivier","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3892\/ijo.2024.5668","article-title":"Targeting drug resistance in glioblastoma (review)","volume":"65","author":"Sherman","year":"2024","journal-title":"Int. J. Oncol."},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb0085","article-title":"Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM)","volume":"15","author":"Alamarty","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hemonc.2021.05.006","article-title":"The phenomenon of multidrug resistance in glioblastomas","volume":"15","author":"Chernov","year":"2022","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/ijms22010351","article-title":"Molecular mechanisms of treatment resistance in glioblastoma","volume":"22","author":"Ou","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0100","first-page":"3","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bioadv.2026.214829_bb0105","article-title":"Management of glioblastoma in elderly patients: a review of the literature","volume":"46","author":"Mazarakis","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0110","first-page":"364","article-title":"Safe surgery for glioblastoma: recent advances and modern challenges","volume":"9","author":"Gerritsen","year":"2022","journal-title":"Neurooncol. Pract."},{"issue":"18","key":"10.1016\/j.bioadv.2026.214829_bb0115","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.3390\/jcm11185354","article-title":"Surgical treatment of glioblastoma: state-of-the-art and future trends","volume":"11","author":"Sales","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bioadv.2026.214829_bb0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-319-12048-5_4","article-title":"Radiation therapy of glioblastoma","volume":"163","author":"Barani","year":"2015","journal-title":"Cancer Treat. Res."},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2016.70.7562","article-title":"Radiation therapy for glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline","volume":"35","author":"Sulman","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioadv.2026.214829_bb0130","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3389\/fneur.2017.00748","article-title":"Advances in radiotherapy for glioblastoma","volume":"8","author":"Mann","year":"2018","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-021-01962-8","volume":"16","author":"K\u00f6nig","year":"2021","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.bioadv.2026.214829_bb0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/2152-7806.132138","article-title":"Glioblastoma multiforme: state of the art and future therapeutics","volume":"5","author":"Wilson","year":"2014","journal-title":"Surg. Neurol. Int."},{"issue":"8","key":"10.1016\/j.bioadv.2026.214829_bb0145","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/brain\/awz202","article-title":"Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2","volume":"142","author":"Yi","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.bioadv.2026.214829_bb0150","first-page":"513","article-title":"Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41419-019-2200-2","article-title":"Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma","volume":"11","author":"Rab\u00e9","year":"2020","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.bioadv.2026.214829_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25063217","article-title":"A review of approaches to potentiate the activity of temozolomide against glioblastoma to overcome resistance","volume":"25","author":"Karve","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-021-00717-7","article-title":"Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma","volume":"28","author":"Chien","year":"2021","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1078155220909426","article-title":"Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma","volume":"27","author":"Tas","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"6","key":"10.1016\/j.bioadv.2026.214829_bb0175","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1097\/MJT.0000000000001186","article-title":"Complete response to temozolomide in metastatic melanoma after failure of 5 lines of treatment","volume":"29","author":"Magge","year":"2022","journal-title":"Am. J. Ther."},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/092986709787002718","article-title":"Recent approaches to improve the antitumor efficacy of temozolomide","volume":"16","author":"Tentori","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioadv.2026.214829_bb0185","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2002.01.030","article-title":"Phase I study of temozolomide in relapsed\/refractory acute leukemia","volume":"20","author":"Seiter","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bioadv.2026.214829_bb0190","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0195","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/cncr.25035","article-title":"Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects","volume":"116","author":"Neyns","year":"2010","journal-title":"Cancer"},{"issue":"7\u20138","key":"10.1016\/j.bioadv.2026.214829_bb0200","first-page":"444","article-title":"Temozolomide-related hematologic toxicity","volume":"36","author":"Scaringi","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.bioadv.2026.214829_bb0205","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2147\/DDDT.S305792","article-title":"Toxicities and associated factors in patients receiving temozolomide-containing regimens: a 12-year analysis of hospital data","volume":"15","author":"Shi","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb0210","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3346\/jkms.2014.29.7.980","article-title":"Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea","volume":"29","author":"Bae","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.bioadv.2026.214829_bb0215","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jconrel.2022.08.024","article-title":"Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme","volume":"350","author":"Jatyan","year":"2022","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0220","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/1061186X.2022.2119243","article-title":"Progress in research and development of temozolomide brain-targeted preparations: a review","volume":"31","author":"Yang","year":"2023","journal-title":"J. Drug Target."},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0225","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/ijms26051814","article-title":"Nanotherapy of glioblastoma-where hope grows","volume":"26","author":"Grzegorzewski","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioadv.2026.214829_bb0230","first-page":"1","article-title":"Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment","author":"Zarneshan","year":"2025","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.bioadv.2026.214829_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2025.214221","article-title":"Advanced nanomicelles for targeted glioblastoma multiforme therapy","volume":"170","author":"Chithra","year":"2025","journal-title":"Biomater. Adv."},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5114\/fn.2023.126886","article-title":"Nanotechnology-based cancer chemoprevention in glioblastoma","volume":"61","author":"Adylova","year":"2023","journal-title":"Folia Neuropathol."},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0245","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1039\/D2BM01996E","article-title":"Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery","volume":"11","author":"Nozhat","year":"2023","journal-title":"Biomater. Sci."},{"issue":"10","key":"10.1016\/j.bioadv.2026.214829_bb0250","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/nano13101619","article-title":"Platinum-based nanoformulations for glioblastoma treatment: the resurgence of platinum drugs?","volume":"13","author":"Alfonso-Triguero","year":"2023","journal-title":"Nanomaterials"},{"issue":"22","key":"10.1016\/j.bioadv.2026.214829_bb0255","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.2174\/1381612829666230703113141","article-title":"Brain-targeted nano-architectures for efficient drug delivery and sensitization in glioblastoma","volume":"29","author":"Ravuluri","year":"2023","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0260","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1039\/D2BM01534J","article-title":"Injectable local drug delivery systems for glioblastoma: a systematic review and meta-analysis of progress to date","volume":"11","author":"Wang","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.bioadv.2026.214829_bb0265","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.15571","article-title":"Functionalized nanoparticles crossing the brain-blood barrier to target glioma cells","volume":"11","author":"Wu","year":"2023","journal-title":"PeerJ"},{"issue":"Pt 2","key":"10.1016\/j.bioadv.2026.214829_bb0270","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.semcancer.2022.06.007","article-title":"Nanomedicine for glioblastoma: progress and future prospects","volume":"86","author":"Khan","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"11","key":"10.1016\/j.bioadv.2026.214829_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27113507","article-title":"Temozolomide efficacy and metabolism: the implicit relevance of nanoscale delivery systems","volume":"27","author":"Petrenko","year":"2022","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0280","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14715","article-title":"Nanoparticles for efficient drug delivery and drug resistance in glioma: new perspectives","volume":"30","author":"Liu","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"14","key":"10.1016\/j.bioadv.2026.214829_bb0285","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.7150\/jca.96859","article-title":"Nanotechnology as a new strategy for the diagnosis and treatment of gliomas","volume":"15","author":"Lei","year":"2024","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/j.bioadv.2026.214829_bb0290","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/10937404.2024.2326679","article-title":"Application of nanoformulations as a strategy to optimize chemotherapeutic treatment of glioblastoma: a systematic review","volume":"27","author":"de Oliveira","year":"2024","journal-title":"J. Toxicol. Environ. Health B."},{"key":"10.1016\/j.bioadv.2026.214829_bb0295","article-title":"Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations","author":"Mandal","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.bioadv.2026.214829_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117754","article-title":"Exosomes as nature's nano carriers: promising drug delivery tools and targeted therapy for glioma","volume":"182","author":"Rana","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioadv.2026.214829_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125540","article-title":"Self-Assembled systems for Nose-to-Brain delivery of Temozolamide (TMZ) in brain tumor therapy","volume":"675","author":"Bhagat","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0310","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1022592913323","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates","volume":"61","author":"Patel","year":"2003","journal-title":"J. Neurooncol"},{"issue":"11","key":"10.1016\/j.bioadv.2026.214829_bb0315","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"1\u20133","key":"10.1016\/j.bioadv.2026.214829_bb0320","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.chemphys.2011.07.014","article-title":"A quantum theoretical study of reactions of methyldiazonium ion with DNA base pairs","volume":"388","author":"Shukla","year":"2011","journal-title":"Chem. Phys."},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0325","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1021\/tx060164e","article-title":"Methylating agents and DNA repair responses: methylated bases and sources of strand breaks","volume":"19","author":"Wyatt","year":"2006","journal-title":"Chem. Res. Toxicol."},{"issue":"10","key":"10.1016\/j.bioadv.2026.214829_bb0330","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0335","first-page":"391","article-title":"DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance","volume":"21","author":"Kyrtopoulos","year":"1997","journal-title":"Cancer Detect. Prev."},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0340","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/bies.10063","article-title":"O-6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy","volume":"24","author":"Margison","year":"2002","journal-title":"Bioessays"},{"key":"10.1016\/j.bioadv.2026.214829_bb0345","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2017.10.017","article-title":"Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response","volume":"184","author":"Hombach-Klonisch","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"15","key":"10.1016\/j.bioadv.2026.214829_bb0350","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1002\/j.1460-2075.1996.tb00778.x","article-title":"The nuclear targeting and nuclear retention properties of a human DNA repair protein O6-methylguanine-DNA methyltransferase are both required for its nuclear localization: the possible implications","volume":"15","author":"Lim","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.bioadv.2026.214829_bb0355","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0079-6603(08)60879-X","article-title":"Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase","volume":"51","author":"Pegg","year":"1995","journal-title":"Prog. Nucleic Acid Res. Mol. Biol."},{"issue":"10","key":"10.1016\/j.bioadv.2026.214829_bb0360","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bioadv.2026.214829_bb0365","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/(SICI)1097-0215(19990820)84:4<416::AID-IJC15>3.0.CO;2-A","article-title":"O(6)methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation","volume":"84","author":"Rolhion","year":"1999","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bioadv.2026.214829_bb0370","first-page":"785","article-title":"A single cycle of treatment with temozolomide, alone or combined with O-6-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: Role of O-6-methylguanine-DNA methyltransferase and the mismatch repair system","volume":"29","author":"Alvino","year":"2006","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0375","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bioadv.2026.214829_bb0380","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.1158\/1078-0432.CCR-09-1245","article-title":"ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors","volume":"15","author":"Palma","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.bioadv.2026.214829_bb0385","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1073\/pnas.87.14.5368","article-title":"Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents","volume":"87","author":"Dolan","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0390","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ijc.10532","article-title":"Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model","volume":"100","author":"Middleton","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0395","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11060-011-0709-z","article-title":"A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study","volume":"106","author":"Warren","year":"2012","journal-title":"J. Neurooncol"},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0400","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0405","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3892\/mco.2025.2913","article-title":"Drug resistance in glioblastoma: challenges, mechanisms and therapeutic strategies (review)","volume":"24","author":"Durga","year":"2025","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.bioadv.2026.214829_bb0410","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","article-title":"Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies","volume":"24","author":"Pouyan","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0415","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clineuro.2012.04.005","article-title":"The influence of surgery on recurrence pattern of glioblastoma","volume":"115","author":"De Bonis","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.bioadv.2026.214829_bb0420","doi-asserted-by":"crossref","first-page":"786","DOI":"10.2174\/092986710790514507","article-title":"The structure and functions of P-glycoprotein","volume":"17","author":"Li","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0425","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0430","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/aps.2009.199","article-title":"Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations","volume":"31","author":"Gao","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioadv.2026.214829_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156575","article-title":"Enhancing temozolomide efficacy in GBM: The synergistic role of chuanxiong rhizoma essential oil","volume":"140","author":"Ke","year":"2025","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0440","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-010-0186-9","article-title":"Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance","volume":"100","author":"Kitange","year":"2010","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.bioadv.2026.214829_bb0445","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fphar.2020.00368","article-title":"Targeting tumor associated macrophages to overcome conventional treatment resistance in glioblastoma","volume":"11","author":"Gr\u00e9goire","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"18","key":"10.1016\/j.bioadv.2026.214829_bb0450","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/cells14181458","article-title":"Tumor-associated macrophages in glioblastoma: mechanisms of tumor progression and therapeutic strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.bioadv.2026.214829_bb0455","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.3390\/cancers13174255","article-title":"Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy","volume":"13","author":"Andersen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioadv.2026.214829_bb0460","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1186\/s12885-025-15163-z","article-title":"Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression","volume":"25","author":"Estabillo","year":"2025","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0465","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/glioma.glioma_24_22","article-title":"Research progress of drug resistance mechanisms to temozolomide in glioblastoma: a narrative review","volume":"5","author":"Lu","year":"2022","journal-title":"Glioma"},{"issue":"8","key":"10.1016\/j.bioadv.2026.214829_bb0470","first-page":"3742","article-title":"Extracellular matrix in glioblastoma: opportunities for emerging therapeutic approaches","volume":"11","author":"Mohiuddin","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioadv.2026.214829_bb0475","first-page":"12","article-title":"The epigenetic mechanisms involved in the treatment resistance of glioblastoma","volume":"8","author":"Shahani","year":"2025","journal-title":"Cancer Drug Resist."},{"issue":"15","key":"10.1016\/j.bioadv.2026.214829_bb0480","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.3390\/ijms22158324","article-title":"The impact of epigenetic modifications on adaptive resistance evolution in glioblastoma","volume":"22","author":"Wu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioadv.2026.214829_bb0485","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-021-00491-w","article-title":"The adaptive transition of glioblastoma stem cells and its implications on treatments","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioadv.2026.214829_bb0490","article-title":"Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance","volume":"13","author":"D'Aprile","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0495","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ph6121475","article-title":"Glioblastoma multiforme therapy and mechanisms of resistance","volume":"6","author":"Ramirez","year":"2013","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0500","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.xphs.2024.11.030","article-title":"Targeted thermosensitive liposomes loaded with gold nanoparticles and temozolomide hexadecanoate for the synergistic photothermal-chemotherapy treatment of glioblastoma","volume":"114","author":"Duan","year":"2025","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.bioadv.2026.214829_bb0505","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/jnt3040012","article-title":"Antibody delivery into the brain by radiosensitizer nanoparticles for targeted glioblastoma therapy","volume":"3","author":"Gal","year":"2022","journal-title":"J. Nanotheranostics"},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210032","article-title":"Evaluation of radiosensitization and cytokine modulation by differentially PEGylated gold nanoparticles in glioblastoma cells","volume":"24","author":"Kerr","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.bioadv.2026.214829_bb0515","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.3390\/nano13212821","article-title":"Harnessing nuclear energy to gold nanoparticles for the concurrent chemoradiotherapy of glioblastoma","volume":"13","author":"Li","year":"2023","journal-title":"Nanomaterials"},{"key":"10.1016\/j.bioadv.2026.214829_bb0520","doi-asserted-by":"crossref","DOI":"10.2196\/49417","article-title":"Targeted glioblastoma treatment via synthesis and functionalization of gold nanoparticles with de novo-engineered transferrin-like peptides: protocol for a novel method","volume":"12","author":"M\u00fcller Fiedler","year":"2023","journal-title":"JMIR Res. Protoc."},{"issue":"4","key":"10.1016\/j.bioadv.2026.214829_bb0525","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1021\/acs.molpharmaceut.2c00083","article-title":"Efficacy of temozolomide-conjugated gold nanoparticle photothermal therapy of drug-resistant glioblastoma and its mechanism study","volume":"19","author":"Yu","year":"2022","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.bioadv.2026.214829_bb0530","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1021\/acsami.5b10883","article-title":"Approach to rapid synthesis and functionalization of iron oxide nanoparticles for high gene transfection","volume":"8","author":"Stephen","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0535","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/acsami.2c17802","article-title":"Iron oxide nanoparticles decorated with functional peptides for a targeted siRNA delivery to glioma cells","volume":"15","author":"Chung","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0540","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1039\/B9PY00216B","article-title":"Thiol-ene \u201cclick\u201d reactions and recent applications in polymer and materials synthesis","volume":"1","author":"Lowe","year":"2010","journal-title":"Polym. Chem."},{"issue":"33","key":"10.1016\/j.bioadv.2026.214829_bb0545","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.1021\/ja305441d","article-title":"Thiol-ene click chemistry: computational and kinetic analysis of the influence of alkene functionality","volume":"134","author":"Northrop","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioadv.2026.214829_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1363511","article-title":"Diethyldithiocarbamate-ferrous oxide nanoparticles inhibit human and mouse glioblastoma stemness: aldehyde dehydrogenase 1A1 suppression and ferroptosis induction","volume":"15","author":"Abu-Serie","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioadv.2026.214829_bb0555","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1179343","article-title":"Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells","volume":"10","author":"Chen","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioadv.2026.214829_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120729","article-title":"Sensitization of glioblastoma cancer cells to radiotherapy and magnetic hyperthermia by targeted temozolomide-loaded magnetite tri-block copolymer nanoparticles as a nanotheranostic agent","volume":"306","author":"Minaei","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0565","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12929-025-01126-w","article-title":"IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment","volume":"32","author":"Lee","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0570","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.1038\/s41598-025-95544-3","article-title":"Magnetic hyperthermia therapy enhances the chemoradiosensitivity of glioblastoma","volume":"15","author":"Rivera","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioadv.2026.214829_bb0575","first-page":"1","article-title":"Cancer cell membrane-camouflaged biomimetic nanoparticles for enhancing chemo-radiation therapy efficacy in glioma","author":"Tang","year":"2024","journal-title":"J. Biomed. Res."},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0580","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.3390\/ijms23052874","article-title":"Synthesis of MIL-modified Fe3O4 magnetic nanoparticles for enhancing uptake and efficiency of temozolomide in glioblastoma treatment","volume":"23","author":"Pulvirenti","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.bioadv.2026.214829_bb0585","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1080\/09205063.2024.2364533","article-title":"Fabrication of pH-responsive temozolomide (TMZ)-clacked tannic acid-altered zeolite imidazole nanoframeworks (ZIF-8) enhance anticancer activity and apoptosis induction in glioma cancer cells","volume":"35","author":"Ren","year":"2024","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0590","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7150\/ntno.76559","article-title":"Development of a personalised device for systemic magnetic drug targeting to brain tumours","volume":"7","author":"Patel","year":"2023","journal-title":"Nanotheranostics"},{"issue":"8","key":"10.1016\/j.bioadv.2026.214829_bb0595","article-title":"Temozolomide and chloroquine co-loaded mesoporous silica nanoparticles are effective against glioma","volume":"9","author":"Zhang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bioadv.2026.214829_bb0600","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2023.03.040","article-title":"Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma","volume":"357","author":"Janjua","year":"2023","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0605","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1021\/acs.molpharmaceut.2c00763","article-title":"A Multifunctional porous silicon nanocarrier for glioblastoma treatment","volume":"20","author":"Luo","year":"2023","journal-title":"Mol. Pharm."},{"issue":"17","key":"10.1016\/j.bioadv.2026.214829_bb0610","doi-asserted-by":"crossref","first-page":"21722","DOI":"10.1021\/acsami.4c04289","article-title":"Overcoming the blood-brain tumor barrier with docetaxel-loaded mesoporous silica nanoparticles for treatment of temozolomide-resistant glioblastoma","volume":"16","author":"Hsu","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bioadv.2026.214829_bb0615","doi-asserted-by":"crossref","DOI":"10.1039\/D4TB00631C","article-title":"Use of surface-modified porous silicon nanoparticles to deliver temozolomide with enhanced pharmacokinetic and therapeutic efficacy for intracranial glioblastoma in mice","author":"Shin","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bioadv.2026.214829_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122479","article-title":"Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating temozolomide for synergistic glioblastoma therapy","volume":"306","author":"Fei","year":"2024","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0625","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12951-024-02531-3","article-title":"Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma","volume":"22","author":"Chen","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0630","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/acs.molpharmaceut.4c00817","article-title":"Oxygen\/Nitric Oxide Dual-Releasing Nanozyme for Augmenting TMZ-Mediated Apoptosis and Necrosis","volume":"22","author":"Ma","year":"2025","journal-title":"Mol. Pharm."},{"issue":"15","key":"10.1016\/j.bioadv.2026.214829_bb0635","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1021\/ja028650l","article-title":"A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules","volume":"125","author":"Lai","year":"2003","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.bioadv.2026.214829_bb0640","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201605985","article-title":"A drug-self-gated mesoporous antitumor nanoplatform based on pH-sensitive dynamic covalent bond","volume":"27","author":"Zeng","year":"2017","journal-title":"Adv. Funct. Mater."},{"issue":"10","key":"10.1016\/j.bioadv.2026.214829_bb0645","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1021\/acsbiomaterials.1c00653","article-title":"A deep dive: SIWV tetra-peptide enhancing the penetration of nanotherapeutics into the glioblastoma","volume":"8","author":"Kang","year":"2022","journal-title":"ACS Biomater Sci. Eng."},{"issue":"78","key":"10.1016\/j.bioadv.2026.214829_bb0650","doi-asserted-by":"crossref","first-page":"10941","DOI":"10.1039\/D2CC03777G","article-title":"SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy","volume":"58","author":"Park","year":"2022","journal-title":"Chem. Commun."},{"issue":"6","key":"10.1016\/j.bioadv.2026.214829_bb0655","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1021\/acssensors.1c00320","article-title":"Human glioblastoma visualization: triple receptor-targeting fluorescent complex of dye, SIWV tetra-peptide, and serum albumin protein","volume":"6","author":"An","year":"2021","journal-title":"ACS Sens."},{"key":"10.1016\/j.bioadv.2026.214829_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213442","article-title":"Targeted delivery of temozolomide by nanocarriers based on folic acid-hollow TiO2-nanospheres for the treatment of glioblastoma","volume":"151","author":"Uribe-Robles","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.bioadv.2026.214829_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106319","article-title":"Blood-brain barrier permeable and multi-stimuli responsive nanoplatform for orthotopic glioma inhibition by synergistic enhanced chemo-\/chemodynamic\/photothermal\/starvation therapy","volume":"180","author":"Cao","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioadv.2026.214829_bb0670","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jconrel.2023.01.023","article-title":"Bio-fabricated nanodrugs with chemo-immunotherapy to inhibit glioma proliferation and recurrence","volume":"354","author":"Wang","year":"2023","journal-title":"J. Control. Release"},{"issue":"34","key":"10.1016\/j.bioadv.2026.214829_bb0675","doi-asserted-by":"crossref","first-page":"38617","DOI":"10.1021\/acsami.2c12348","article-title":"Reducing chemo-\/radioresistance to boost the therapeutic efficacy against temozolomide-resistant glioblastoma","volume":"14","author":"Yun","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1093","key":"10.1016\/j.bioadv.2026.214829_bb0680","article-title":"AGuIX\u00ae from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine","volume":"92","author":"Lux","year":"2019","journal-title":"Br. J. Radiol."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0685","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12885-023-10829-y","article-title":"Phase I\/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)","volume":"23","author":"Thivat","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioadv.2026.214829_bb0690","article-title":"NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed glioblastoma: phase 1b outcomes and MRI-based biodistribution","volume":"48","author":"Biau","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.bioadv.2026.214829_bb0695","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s11671-023-03880-y","article-title":"Applications of drug delivery systems, organic, and inorganic nanomaterials in wound healing","volume":"18","author":"Lo","year":"2023","journal-title":"Discover Nano"},{"key":"10.1016\/j.bioadv.2026.214829_bb0700","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s11671-023-03943-0","article-title":"Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review","volume":"18","author":"Unnikrishnan","year":"2023","journal-title":"Discover Nano"},{"key":"10.1016\/j.bioadv.2026.214829_bb0705","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819853241","article-title":"Inorganic nanoparticles as drug delivery systems and their potential role in the treatment of chronic myelogenous leukaemia","volume":"18","author":"Ghosn","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.bioadv.2026.214829_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.coche.2022.100869","article-title":"Inorganic nanoparticles for oral drug delivery: opportunities, barriers, and future perspectives","volume":"38","author":"Asad","year":"2022","journal-title":"Curr. Opin. Chem. Eng."},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb0715","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1517\/17425247.2014.913568","article-title":"Advantages and risks of nanotechnologies in cancer patients and occupationally exposed workers","volume":"11","author":"Lamberti","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0720","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/13892002113149990008","article-title":"Engineered inorganic nanoparticles for drug delivery applications","volume":"14","author":"Ojea-Jim\u00e9nez","year":"2013","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0725","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/micro5010002","article-title":"Lipidic and inorganic nanoparticles for targeted glioblastoma multiforme therapy: advances and strategies","volume":"5","author":"Musielak","year":"2025","journal-title":"Micro"},{"key":"10.1016\/j.bioadv.2026.214829_bb0730","doi-asserted-by":"crossref","first-page":"9823","DOI":"10.2147\/IJN.S279094","article-title":"A review on the synthesis and functionalization of gold nanoparticles as a drug delivery vehicle","volume":"15","author":"Amina","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioadv.2026.214829_bb0735","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.biopha.2018.10.167","article-title":"Mesoporous silica nanoparticles for therapeutic\/diagnostic applications","volume":"109","author":"Jafari","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"20","key":"10.1016\/j.bioadv.2026.214829_bb0740","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.3390\/nano12203686","article-title":"SPIONs conjugate supported anticancer drug doxorubicin's delivery: current status, challenges, and prospects","volume":"12","author":"Akhtar","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.bioadv.2026.214829_bb0745","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.progpolymsci.2018.07.005","article-title":"Pharmapolymers in the 21st century: synthetic polymers in drug delivery applications","volume":"87","author":"Englert","year":"2018","journal-title":"Prog. Polym. Sci."},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0750","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3390\/polym12122881","article-title":"Progress and prospects of polymer-based drug delivery systems for bone tissue regeneration","volume":"12","author":"Ogay","year":"2020","journal-title":"Polymers"},{"key":"10.1016\/j.bioadv.2026.214829_bb0755","article-title":"Temozolomide hexadecyl ester targeted PLGA nanoparticles for drug-resistant glioblastoma therapy via intranasal administration","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0760","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1021\/cr040002s","article-title":"Controlled ring-opening polymerization of lactide and glycolide","volume":"104","author":"Dechy-Cabaret","year":"2004","journal-title":"Chem. Rev."},{"issue":"11","key":"10.1016\/j.bioadv.2026.214829_bb0765","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/10601320903252090","article-title":"Study of different catalysts and initiators in bulk copolymerization of d,l-lactide and glycolide","volume":"46","author":"Mazarro","year":"2009","journal-title":"J. Macromol. Sci. Part A"},{"issue":"18","key":"10.1016\/j.bioadv.2026.214829_bb0770","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.3390\/molecules27185757","article-title":"Oncolytic newcastle disease virus co-delivered with modified PLGA nanoparticles encapsulating temozolomide against glioblastoma cells: developing an effective treatment strategy","volume":"27","author":"Kadhim","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioadv.2026.214829_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114326","article-title":"Chitosan-PLGA mucoadhesive nanoparticles for gemcitabine repurposing for glioblastoma therapy","volume":"200","author":"Ramalho","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0780","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1021\/acsami.4c16837","article-title":"Nose-to-brain delivery of biomimetic nanoparticles for glioblastoma targeted therapy","volume":"17","author":"Ferreira","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bioadv.2026.214829_bb0785","article-title":"Small molecule based EGFR targeting of biodegradable nanoparticles containing temozolomide and Cy5 dye for greatly enhanced image-guided glioblastoma therapy","volume":"41","author":"Schmitt","year":"2022","journal-title":"Nanomedicine"},{"issue":"15","key":"10.1016\/j.bioadv.2026.214829_bb0790","doi-asserted-by":"crossref","first-page":"14191","DOI":"10.1021\/acsanm.3c02122","article-title":"Transferrin-conjugated PLGA nanoparticles for co-delivery of temozolomide and bortezomib to glioblastoma cells","volume":"6","author":"Ramalho","year":"2023","journal-title":"ACS Appl. Nano Mater."},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0795","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/ad1bb2","article-title":"Amrubicin encapsulated PLGA NPs inhibits the PI3K\/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma","volume":"19","author":"Younis","year":"2024","journal-title":"Biomed. Mater."},{"issue":"6","key":"10.1016\/j.bioadv.2026.214829_bb0800","doi-asserted-by":"crossref","first-page":"eabq7459","DOI":"10.1126\/sciadv.abq7459","article-title":"Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy","volume":"9","author":"Wang","year":"2023","journal-title":"Sci. Adv."},{"issue":"44","key":"10.1016\/j.bioadv.2026.214829_bb0805","article-title":"A Trojan-horse-like biomimetic nano-NK to elicit an immunostimulatory tumor microenvironment for enhanced GBM chemo-immunotherapy","volume":"19","author":"Zhang","year":"2023","journal-title":"Small"},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb0810","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202403108","article-title":"NIR-II photoacoustic imaging-guided chemo-photothermal therapy using PA1094T combined with anti-CD47 antibody: activating pyroptosis against orthotopic glioblastoma","volume":"14","author":"Li","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bioadv.2026.214829_bb0815","article-title":"Intelligent nanoparticles with pH-sensitive co-delivery of temozolomide and siEGFR to ameliorate glioma therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.bioadv.2026.214829_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101122","article-title":"Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma","volume":"76","author":"Lan","year":"2024","journal-title":"Drug Resist. Updat."},{"issue":"29","key":"10.1016\/j.bioadv.2026.214829_bb0825","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202400502","article-title":"Dual-targeted novel temozolomide nanocapsules encapsulating siPKM2 inhibit aerobic glycolysis to sensitize glioblastoma to chemotherapy","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bioadv.2026.214829_bb0830","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jconrel.2022.07.027","article-title":"MicroRNA delivery systems in glioma therapy and perspectives: a systematic review","volume":"349","author":"Jim\u00e9nez-Morales","year":"2022","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0835","doi-asserted-by":"crossref","first-page":"12017","DOI":"10.1038\/s41598-022-16219-x","article-title":"A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models","volume":"12","author":"Sadeghipour","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioadv.2026.214829_bb0840","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2024.11.039","article-title":"Self-assembling nanoparticles for delivery of miR-603 and miR-221 in glioblastoma as a new strategy to overcome resistance to temozolomide","volume":"377","author":"Abate","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2026.214829_bb0845","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2023.05.043","article-title":"Yeast cell membrane-camouflaged PLGA nanoparticle platform for enhanced cancer therapy","volume":"359","author":"He","year":"2023","journal-title":"J. Control. Release"},{"issue":"720","key":"10.1016\/j.bioadv.2026.214829_bb0850","doi-asserted-by":"crossref","first-page":"eadi1617","DOI":"10.1126\/scitranslmed.adi1617","article-title":"Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma","volume":"15","author":"Khang","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0855","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/21691401.2014.955108","article-title":"A comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line","volume":"44","author":"Tabatabaei Mirakabad","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"18","key":"10.1016\/j.bioadv.2026.214829_bb0860","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1021\/ma201169z","article-title":"A strategy for control of \u201cRandom\u201d copolymerization of lactide and glycolide: application to synthesis of PEG-b-PLGA block polymers having narrow dispersity","volume":"44","author":"Qian","year":"2011","journal-title":"Macromolecules"},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0865","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/pharmaceutics17020191","article-title":"Exploratory study on nanoparticle co-delivery of temozolomide and ligustilide for enhanced brain tumor therapy","volume":"17","author":"Ke","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0870","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1021\/acs.molpharmaceut.4c00708","article-title":"Intracranial nanogel pellets carrying temozolomide and paclitaxel for adjuvant brain cancer therapy","volume":"22","author":"Slika","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioadv.2026.214829_bb0875","article-title":"Lactate-coated polyurea-siRNA dendriplex: a gene therapy-directed and metabolism-based strategy to impair glioblastoma (GBM)","author":"Martins","year":"2025","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0880","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s13346-021-01017-1","article-title":"Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance","volume":"12","author":"Behrooz","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb0885","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1021\/acsbiomaterials.3c00263","article-title":"Angiopep-2 grafted PAMAM dendrimers for the targeted delivery of temozolomide: in vitro and in vivo effects of PEGylation in the management of glioblastoma multiforme","volume":"9","author":"Sahoo","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb0890","doi-asserted-by":"crossref","DOI":"10.1007\/s11051-019-4486-5","article-title":"PEGylated poly(amidoamine) dendrimers-based drug loading vehicles for delivering carboplatin in treatment of various cancerous cells","volume":"21","author":"Ho","year":"2019","journal-title":"J. Nanopart. Res."},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0895","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1021\/acs.accounts.0c00589","article-title":"Self-assembling supramolecular dendrimers for biomedical applications: lessons learned from poly(amidoamine) dendrimers","volume":"53","author":"Lyu","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bioadv.2026.214829_bb0900","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mtchem.2019.04.004","article-title":"Poly(amidoamine) dendrimers: covalent and supramolecular synthesis","volume":"13","author":"Lyu","year":"2019","journal-title":"Mater. Today Chem."},{"issue":"18","key":"10.1016\/j.bioadv.2026.214829_bb0905","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202207248","article-title":"Polyhedral oligomeric silsesquioxane-based nanoparticles for efficient chemotherapy of glioblastoma","volume":"19","author":"Zhong","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.bioadv.2026.214829_bb0910","article-title":"Polydopamine-based loaded temozolomide nanoparticles conjugated by peptide-1 for glioblastoma chemotherapy and photothermal therapy","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"17","key":"10.1016\/j.bioadv.2026.214829_bb0915","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/cbic.201900030","article-title":"Expanding the DOPA universe with genetically encoded, mussel-inspired bioadhesives for material sciences and medicine","volume":"20","author":"Budisa","year":"2019","journal-title":"ChemBioChem"},{"issue":"33","key":"10.1016\/j.bioadv.2026.214829_bb0920","doi-asserted-by":"crossref","first-page":"10539","DOI":"10.1021\/la4020288","article-title":"Structure of polydopamine: a never-ending story?","volume":"29","author":"Liebscher","year":"2013","journal-title":"Langmuir"},{"key":"10.1016\/j.bioadv.2026.214829_bb0925","article-title":"Adjustable synthesis of polydopamine nanospheres and their nucleation and growth","author":"Meng","year":"2020","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"issue":"16","key":"10.1016\/j.bioadv.2026.214829_bb0930","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.3390\/ma17163916","article-title":"Polydopamine applications in biomedicine and environmental science","volume":"17","author":"Omidian","year":"2024","journal-title":"Materials"},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb0935","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/03639045.2024.2332906","article-title":"Temozolomide nano-in-nanofiber delivery system with sustained release and enhanced cellular uptake by U87MG cells","volume":"50","author":"Shetty","year":"2024","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb0940","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3390\/biomedicines12071393","article-title":"Rational design of pectin-chitosan polyelectrolyte nanoparticles for enhanced temozolomide delivery in brain tumor therapy","volume":"12","author":"Silant'ev","year":"2024","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0945","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1021\/am5092165","article-title":"Temozolomide nanoparticles for targeted glioblastoma therapy","volume":"7","author":"Fang","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb0950","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/jpp\/rgad020","article-title":"The interplay of solvent-drug-protein interactions during albumin nanoparticles formulations for temozolomide delivery to brain cancer cells","volume":"75","author":"Helal","year":"2023","journal-title":"J. Pharm. Pharmacol."},{"issue":"10","key":"10.1016\/j.bioadv.2026.214829_bb0955","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/s41416-023-02225-x","article-title":"Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma","volume":"128","author":"Kiang","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0960","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/acsnano.2c07264","article-title":"Molecular recognition and in vivo detection of temozolomide and 5-aminoimidazole-4-carboxamide for glioblastoma using near-infrared fluorescent carbon nanotube sensors","volume":"17","author":"Son","year":"2023","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb0965","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2217\/nnm-2023-0058","article-title":"Curcumin combining temozolomide formed localized nanogel for inhibition of postsurgical chemoresistant glioblastoma","volume":"18","author":"Liang","year":"2023","journal-title":"Nanomedicine"},{"issue":"35","key":"10.1016\/j.bioadv.2026.214829_bb0970","doi-asserted-by":"crossref","first-page":"12773","DOI":"10.1039\/D2NR00171C","article-title":"Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy","volume":"14","author":"Sandbhor","year":"2022","journal-title":"Nanoscale"},{"key":"10.1016\/j.bioadv.2026.214829_bb0975","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jconrel.2022.07.011","article-title":"Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence","volume":"349","author":"Chen","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2026.214829_bb0980","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.carbpol.2014.09.094","article-title":"Glycerophosphate-based chitosan thermosensitive hydrogels and their biomedical applications","volume":"117","author":"Zhou","year":"2015","journal-title":"Carbohydr. Polym."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0985","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1038\/s41598-023-31811-5","article-title":"Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models","volume":"13","author":"Gherardini","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioadv.2026.214829_bb0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121584","article-title":"Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment","volume":"617","author":"Reinhardt","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb0995","doi-asserted-by":"crossref","first-page":"6835","DOI":"10.1038\/s41467-022-34462-8","article-title":"Near infrared-activatable biomimetic nanogels enabling deep tumor drug penetration inhibit orthotopic glioblastoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb1000","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41467-019-13784-0","article-title":"Polydiacetylene-based ultrastrong bioorthogonal Raman probes for targeted live-cell Raman imaging","volume":"11","author":"Tian","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bioadv.2026.214829_bb1005","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/pharmaceutics15020687","article-title":"Glioblastoma multiforme: probing solutions to systemic toxicity towards high-dose chemotherapy and inflammatory influence in resistance against temozolomide","volume":"15","author":"Nasir","year":"2023","journal-title":"Pharmaceutics"},{"issue":"18","key":"10.1016\/j.bioadv.2026.214829_bb1010","doi-asserted-by":"crossref","first-page":"18441","DOI":"10.1021\/acsnano.3c06085","article-title":"Drug-loaded lipid magnetic nanoparticles for combined local hyperthermia and chemotherapy against glioblastoma multiforme","volume":"17","author":"Beola","year":"2023","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb1015","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1021\/acsnano.1c09794","article-title":"Nano-codelivery of temozolomide and siPD-L1 to reprogram the drug-resistant and immunosuppressive microenvironment in orthotopic glioblastoma","volume":"16","author":"Liu","year":"2022","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb1020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/08982104.2021.1998106","article-title":"Investigations on the influence of the structural flexibility of nanoliposomes on their properties","volume":"32","author":"Wang","year":"2022","journal-title":"J. Liposome Res."},{"issue":"23","key":"10.1016\/j.bioadv.2026.214829_bb1025","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.3390\/nano12234233","article-title":"Parenteral nanoemulsions loaded with combined immuno- and chemo-therapy for melanoma treatment","volume":"12","author":"Monge","year":"2022","journal-title":"Nanomaterials"},{"issue":"1","key":"10.1016\/j.bioadv.2026.214829_bb1030","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1080\/10717544.2022.2108938","article-title":"Development of nanocubosomes co-loaded with dual anticancer agents curcumin and temozolomide for effective Colon cancer therapy","volume":"29","author":"Almoshari","year":"2022","journal-title":"Drug Deliv."},{"issue":"10","key":"10.1016\/j.bioadv.2026.214829_bb1035","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1021\/acsami.3c14709","article-title":"Angiopep-2-functionalized lipid cubosomes for blood-brain barrier crossing and glioblastoma treatment","volume":"16","author":"Cai","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"32","key":"10.1016\/j.bioadv.2026.214829_bb1040","doi-asserted-by":"crossref","first-page":"41819","DOI":"10.1021\/acsami.4c05691","article-title":"Targeted delivery of nanoparticle-conveyed neutrophils to the glioblastoma site for efficient therapy","volume":"16","author":"Piao","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"33","key":"10.1016\/j.bioadv.2026.214829_bb1045","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202203958","article-title":"Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy","volume":"34","author":"Zou","year":"2022","journal-title":"Adv. Mater."},{"issue":"24","key":"10.1016\/j.bioadv.2026.214829_bb1050","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ad2d0d","article-title":"IRGD-modified erythrocyte membrane biomimetic temozolomide nanodots for the treatment of glioblastoma","volume":"35","author":"Luo","year":"2024","journal-title":"Nanotechnology"},{"issue":"4","key":"10.1016\/j.bioadv.2026.214829_bb1055","article-title":"Brain co-delivery of first-line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy","volume":"2","author":"Lovejoy","year":"2022","journal-title":"Exploration"},{"key":"10.1016\/j.bioadv.2026.214829_bb1060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.actbio.2025.01.016","article-title":"Macrophage membrane-camouflaged pure-drug nanomedicine for synergistic chemo- and interstitial photodynamic therapy against glioblastoma","volume":"193","author":"Cheng","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bioadv.2026.214829_bb1065","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1120179","article-title":"Using design of experiments (DoE) to optimize performance and stability of biomimetic cell membrane-coated nanostructures for cancer therapy","volume":"11","author":"Ferreira","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"6","key":"10.1016\/j.bioadv.2026.214829_bb1070","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.3390\/ijms24065910","article-title":"Glioblastoma-derived small extracellular vesicles: nanoparticles for glioma treatment","volume":"24","author":"Araujo-Abad","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioadv.2026.214829_bb1075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.partic.2021.04.017","article-title":"Cell membrane-encapsulated nanoparticles for vaccines and immunotherapy","volume":"64","author":"Xiang","year":"2021","journal-title":"Particuology"},{"issue":"9","key":"10.1016\/j.bioadv.2026.214829_bb1080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/jcs7090346","article-title":"Preparation and hydrolytic degradation of hydroxyapatite-filled PLGA composite microspheres","volume":"7","author":"Istratov","year":"2023","journal-title":"J. Compos. Sci."},{"issue":"8","key":"10.1016\/j.bioadv.2026.214829_bb1085","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.3390\/ijms23084153","article-title":"Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology","volume":"23","author":"Hersh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bioadv.2026.214829_bb1090","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb1095","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/polym15071596","article-title":"Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems","volume":"15","author":"Yusuf","year":"2023","journal-title":"Polymers"},{"issue":"5","key":"10.1016\/j.bioadv.2026.214829_bb1100","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/acs.chas.3c00008","article-title":"Toxicity of polymeric nanodrugs as drug carriers","volume":"30","author":"Sairam","year":"2023","journal-title":"ACS Chem. Health Saf."},{"key":"10.1016\/j.bioadv.2026.214829_bb1105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2018.06.023","article-title":"Unintended effects of drug carriers: big issues of small particles","volume":"130","author":"Parhiz","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb1110","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/polym17070833","article-title":"Polymeric nanoparticles in targeted drug delivery: unveiling the impact of polymer characterization and fabrication","volume":"17","author":"Eltaib","year":"2025","journal-title":"Polymers"},{"issue":"11","key":"10.1016\/j.bioadv.2026.214829_bb1115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4155\/tde-2017-0075","article-title":"Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery","volume":"8","author":"Kahraman","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.bioadv.2026.214829_bb1120","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.2147\/IJN.S470478","article-title":"Liposomal nanomaterials: a rising star in glioma treatment","volume":"19","author":"Gan","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb1125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/antiox12030633","article-title":"Solid lipid nanoparticles: review of the current research on encapsulation and delivery systems for active and antioxidant compounds","volume":"12","author":"Subroto","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.bioadv.2026.214829_bb1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111946","article-title":"Brain-targeted, drug-loaded solid lipid nanoparticles against glioblastoma cells in culture","volume":"206","author":"Ak","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"8","key":"10.1016\/j.bioadv.2026.214829_bb1135","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1007\/s13346-022-01135-4","article-title":"Inulin-g-poly-D,L-lactide, a sustainable amphiphilic copolymer for nano-therapeutics","volume":"12","author":"Sardo","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb1140","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.actbio.2010.01.035","article-title":"Complement activation on degraded polyethylene glycol-covered surface","volume":"6","author":"Toda","year":"2010","journal-title":"Acta Biomater."},{"issue":"7","key":"10.1016\/j.bioadv.2026.214829_bb1145","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.bioadv.2026.214829_bb1150","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/neuonc\/nos135","article-title":"In vivo models of primary brain tumors: pitfalls and perspectives","volume":"14","author":"Huszthy","year":"2012","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.bioadv.2026.214829_bb1155","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/acsnano.8b04406","article-title":"Nanomedicine for spontaneous brain tumors: a companion clinical trial","volume":"13","author":"Arami","year":"2019","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.bioadv.2026.214829_bb1160","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3390\/brainsci13121727","article-title":"A systematic review of nanomedicine in glioblastoma treatment: clinical efficacy, safety, and future directions","volume":"13","author":"Farooq","year":"2023","journal-title":"Brain Sci."}],"container-title":["Biomaterials Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950826001275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950826001275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:37:05Z","timestamp":1778935025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772950826001275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":232,"alternative-id":["S2772950826001275"],"URL":"https:\/\/doi.org\/10.1016\/j.bioadv.2026.214829","relation":{},"ISSN":["2772-9508"],"issn-type":[{"value":"2772-9508","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticles for immobilization and delivery of temozolomide: Functional design of carriers, advances, limitations and opportunities for glioblastoma co-therapy","name":"articletitle","label":"Article Title"},{"value":"Biomaterials Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioadv.2026.214829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"214829"}}